EMA Autism Guidance Pushes Sponsors To Tackle Core Symptoms
This article was originally published in The Pink Sheet Daily
Executive Summary
While short-term efficacy in core symptoms should be demonstrated first, EMA draft drug development guidance also calls for a showing of positive effect on global function and maintenance of long-term efficacy.